Last reviewed · How we verify
Neoadjuvant chemotherapy combined with hormone therapy
Neoadjuvant chemotherapy combined with hormone therapy is a Small molecule drug developed by RenJi Hospital. It is currently in Phase 1 development. Also known as: NCHT.
At a glance
| Generic name | Neoadjuvant chemotherapy combined with hormone therapy |
|---|---|
| Also known as | NCHT |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Alopecia
- Nausea
- NAUSEA
- ALOPECIA
- DIARRHOEA
- Diarrhoea
- Fatigue
- Anaemia
- Diarrhea
- FATIGUE
- ANAEMIA
- Arthralgia
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant chemotherapy combined with hormone therapy CI brief — competitive landscape report
- Neoadjuvant chemotherapy combined with hormone therapy updates RSS · CI watch RSS
- RenJi Hospital portfolio CI
Frequently asked questions about Neoadjuvant chemotherapy combined with hormone therapy
What is Neoadjuvant chemotherapy combined with hormone therapy?
Neoadjuvant chemotherapy combined with hormone therapy is a Small molecule drug developed by RenJi Hospital.
Who makes Neoadjuvant chemotherapy combined with hormone therapy?
Neoadjuvant chemotherapy combined with hormone therapy is developed by RenJi Hospital (see full RenJi Hospital pipeline at /company/renji-hospital).
Is Neoadjuvant chemotherapy combined with hormone therapy also known as anything else?
Neoadjuvant chemotherapy combined with hormone therapy is also known as NCHT.
What development phase is Neoadjuvant chemotherapy combined with hormone therapy in?
Neoadjuvant chemotherapy combined with hormone therapy is in Phase 1.
What are the side effects of Neoadjuvant chemotherapy combined with hormone therapy?
Common side effects of Neoadjuvant chemotherapy combined with hormone therapy include Alopecia, Nausea, NAUSEA, ALOPECIA, DIARRHOEA, Diarrhoea.
Related
- Manufacturer: RenJi Hospital — full pipeline
- Also known as: NCHT
- Compare: Neoadjuvant chemotherapy combined with hormone therapy vs similar drugs
- Pricing: Neoadjuvant chemotherapy combined with hormone therapy cost, discount & access